EUVIMEDEUVIMED entdecken
Kohortenstudie

Prolonged remission after cyclophosphamide or tacrolimus treatment in childhood nephrotic syndrome: a cohort study

Cal H Robinson, Nowrin Aman, Tonny Banh, Josefina Brooke, Rahul Chanchlani, Vaneet Dhillon, Valerie Langlois, Leo Levin, Christoph Licht, Ashlene McKay, Damien Noone, Alisha Parikh und 6 weitere

Pediatric Nephrology · 2025

DOI: 10.1007/s00467-024-06605-0 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pediatric Nephrology, 2025. Verfasst von Cal H Robinson und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada. cal.robinson@sickkids.ca. Hauptthemen laut MEDLINE: Tacrolimus, Cyclophosphamide, Nephrotic Syndrome, Immunosuppressive Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Physicians' Services Incorporated Foundation, Sickkids Research Institute, Canada Research Chairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Steroid-sparing immunosuppression is used in 50% of children with nephrotic syndrome, to prevent relapses and steroid-related toxicity. However, rates and predictors of prolonged remission after cyclophosphamide and tacrolimus are uncertain. METHODS: Retrospective analysis of children (1-18 years) enrolled in a longitudinal cohort. We included children diagnosed with steroid-sensitive nephrotic syndrome between 1996-2019 from Toronto, Canada. The exposure was cyclophosphamide or tacrolimus initiation. The primary outcome was prolonged remission (no further relapse or steroid-sparing immunosuppression). We evaluated predictors of prolonged remission and calcineurin inhibitor nephrotoxicity by logistic regression. RESULTS: Of 578 children with steroid-sensitive nephrotic syndrome, 252 received cyclophosphamide and 120 received tacrolimus. Over median 5.4-year (IQR 2.4-9.1) follow-up, prolonged remission occurred in 72 (28.6%) after cyclophosphamide and 17 (14.2%) after tacrolimus. Relapse frequency decreased after initiation of either medication. Lower prior relapse rate, more recent treatment era, and female sex were predictive of prolonged remission after cyclophosphamide treatment. Use of tacrolimus as the first steroid-sparing medication was the only factor predictive of calcineurin inhibitor nephrotoxicity. CONCLUSIONS: Less than one-third of children achieve prolonged remission after initiating cyclophosphamide or tacrolimus, although both reduce short-term relapse rates. Few factors predict prolonged remission after cyclophosphamide or tacrolimus use, or calcineurin inhibitor nephrotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusCyclophosphamideNephrotic SyndromeImmunosuppressive AgentsHumansChildMaleFemaleRetrospective StudiesChild, PreschoolAdolescentRemission InductionInfantRecurrenceCalcineurin InhibitorsLongitudinal StudiesTreatment Outcome

Stichwörter der Autor:innen

Calcineurin inhibitorsChildCyclophosphamideImmunosuppression therapyNephrotic syndromeTacrolimus

Substanzen

TacrolimusCyclophosphamideImmunosuppressive AgentsCalcineurin Inhibitors

Autor:innen und Institutionen

  • Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada. cal.robinson@sickkids.ca.
  • Department of Paediatrics, The University of Toronto, Toronto, ON, Canada. cal.robinson@sickkids.ca.
  • Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada. cal.robinson@sickkids.ca.
  • SickKids Research Institute, Peter Gilgan Centre for Research and Learning, 686 Bay St, Toronto, ON, M5G 0A4, Canada. cal.robinson@sickkids.ca.
  • Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada.
  • Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada.

Förderung

  • Physicians' Services Incorporated Foundation
  • Sickkids Research Institute
  • Canada Research Chairs

Zitieren

APA

Robinson, C. H., Aman, N., Banh, T., Brooke, J., Chanchlani, R., Dhillon, V., Langlois, V., Levin, L., Licht, C., McKay, A., Noone, D., Parikh, A., Pearl, R., Radhakrishnan, S., Rowley, V., Teoh, C. W., Vasilevska-Ristovska, J. H., & Parekh, R. S. (2025). Prolonged remission after cyclophosphamide or tacrolimus treatment in childhood nephrotic syndrome: a cohort study. Pediatric Nephrology. https://doi.org/10.1007/s00467-024-06605-0

Vancouver

Robinson CH, Aman N, Banh T, Brooke J, Chanchlani R, Dhillon V, et al. Prolonged remission after cyclophosphamide or tacrolimus treatment in childhood nephrotic syndrome: a cohort study. Pediatric Nephrology. 2025. doi:10.1007/s00467-024-06605-0

BibTeX
@article{Robinson2025,
  author = {Robinson, Cal H and Aman, Nowrin and Banh, Tonny and Brooke, Josefina and Chanchlani, Rahul and Dhillon, Vaneet and Langlois, Valerie and Levin, Leo and Licht, Christoph and McKay, Ashlene and Noone, Damien and Parikh, Alisha and Pearl, Rachel and Radhakrishnan, Seetha and Rowley, Veronique and Teoh, Chia Wei and Vasilevska-Ristovska, Jovanka H and Parekh, Rulan S},
  title = {Prolonged remission after cyclophosphamide or tacrolimus treatment in childhood nephrotic syndrome: a cohort study},
  journal = {Pediatric Nephrology},
  year = {2025},
  doi = {10.1007/s00467-024-06605-0}
}
Kostenlos starten →